Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Vogelzang
Nicholas J
NJ
Samlowski
Wolfram
W
Weissman
Alan
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D010767:Phosphorylcholine; D009536:Niacinamide; C105905:perifosine; D000077157:Sorafenib; D000077210:Sunitinib